ServiziMenu principaleHome
Home > Programme > Programme



9:00 Patient advocacy session: The do’s and don’ts of complementary medicine
(Chairs: Anna Cabanes, US and Renate Haidinger, DE)
• Complementary medicine: what helps and what doesn’t (Maria João Cardoso, PT)
• New drugs, different side effect: can complementary medicine help? (Christoph Thomssen, DE)
• The danger of being lost between two worlds (Renate Haidinger, DE)
• Panel discussion and Q&A (Moderated by the chairs)
9:00 Sponsored satellite symposium 1 (details are available HERE)
10:30 Coffee break
11:00 Patient advocacy session: Having difficult conversations: Empowering patients and their families with tools and strategies of communication at end of life
(Chairs: Ranjit Kaur, MY, Catherine Priestley, UK and Shawna Rich-Ginsberg, CA)
• Accessing palliative care - Why the resistance? (Matti S. Aapro, CH)
• Navigating end of life conversations with family members and children (Luzia Travado, PT)
• Supporting decision making and advance care planning - A case study of two patients (2 ABC patients)
• Bereavement Support in the MBC Community (Shawna Rich-Ginsberg, CA)
• Discussion
11:00 Sponsored satellite symposium 2 (details are available HERE)
12:30 Lunch
13:30 Opening session (Chairs: Fatima Cardoso, PT and Larry Norton, US)  
• Welcome to Lisbon (Leonor Beleza, President of the Champalimaud Foundation, PT)
• Keynote lecture: a good doctor treats the disease; a great doctor treats the patient with the disease.
   How not to lose the joy of living in the fear of dying (Claire Myerson, UK)
14:20 ABC5 Award and lecture (Chair: Larry Norton, US)
• Making a difference for advanced breast cancer patients (Fatima Cardoso, PT)
14:50 Meaningful clinical benefit: How to define, evaluate and communicate
(Chairs: Bella Kaufman, IL and Shirley A. Mertz, US)
• Applying the ESMO-MBCS to ABC systemic therapies (Shani Paluch-Shimon, IL)
• Optimal endpoints for ABC clinical trials: can we aim for more? (Nadia Harbeck, DE)
• Optimizing clinical trial designs in ABC: reaching relevant clinical benefit (Eric P. Winer, US)
• Estimating and communicating survival times for each ABC patient (Belinda E. Kiely, AU)
• The role of big data and real-world data (George W. Sledge, US)
• Panel Discussion (All)
16:25 Coffee break
16:55 Discussing the hardest issues (Chairs: Anna Cabanes, US and Karen Gelmon, CA)
• When to stop and who decides? (Gabriella Pravettoni, IT)
• Suicide and assisted suicide in ABC patients (Uwe Güth, CH)
• Optimal end of life care (Karen Gelmon, CA)
• Panel discussion: how to support the terminally and family (All)

Patient advocacy session: When cancer becomes visible - living with skin metastases from breast cancer
(Chairs: Bertha Aguilar Lopez, MX, Maria João Cardoso, PT and Gertrude Nakigudde, UG)
• Skin Metastases: the extension of the problem (Maria -Joao Cardoso, PT)
• Do skin metastases have a different biology? (Joana Ribeiro, PT)
• Skin directed therapy: radiotherapy and topical therapy (Birgitte V. Offersen, DK)
• Taking care of malignant wound - what should be considered? (Christine B. Boers-Doets, NL)
• Skin directed therapy: electrochemotherapy, is it a real option? (Giuseppe Curigliano, IT)

• Panel discussion and Q & A (Moderated by the chairs)

18:00 Sponsored satellite symposium 3 (details are available HERE)
19:30 Welcome cocktail  


7:30 Sponsored satellite symposium (TBC)
8:30 Understanding and applying biology knowledge (Chair: Gertrude Nakigudde, UG and Daniel A. Vorobiof, US)
• Next generation sequencing for clinical decisions: friend or foe (Fabrice André, FR)
• Is lobular ABC a separate entity? (Sabine Linn, NL)
• De novo vs. recurrent ABC (Prudence A. Francis, AU)
• Biomarkers for new approaches: what have we been doing wrong? (Aleix Prat, ES)
• Discussion
9:40 Best abstract presentations (Chairs: Alberto Costa, IT and Renate Haidinger, DE)
Femama strategies to ensure HER2+ breast cancer treatments in Brazil (Maria Caleffi, BR)
T-DM1 efficacy and activity in HER2-positive metastatic breast cancer patients progressing after frontline
   taxane plus pertuzumab and trastuzumab: an italian multicenter observational study of the Gruppo
   Italiano Mammella (GIM) study group (Benedetta Conte, IT)
A targeted survey of Belong.Life advanced breast cancer (ABC) patient’s (PTS), focusing on patient’s
   reported outcomes (PROS), real world evidence (RWE) and insights in reducing the burden of financial
   toxicity (FT) (Daniel A. Vorobiof, US)
10:15 Coffee break
10:35 Latest news: Triple negative ABC (Chairs: Kirsten Pilatti, AU and Binghe Xu, CN)
Standards of care and optimal options (Hope S. Rugo, US)
New targets, new drugs (Andrew Tutt, UK)
Biology and resistance (Giuseppe Curigliano, IT)
11:30 Managing side effects and difficult symptoms (Chairs: Jonas Bergh, SE and Renate Haidinger, DE) 
Overcoming global hurdles in pain management: from morphine shortage to opioid abuse (Matti S. Aapro, CH)
Gynecological and sexual symptoms: the silent suffering (Christoph Thomssen, DE)
Fatigue and cachexia: from biology to solutions (Carlos H. Barrios, BR)
12:30 Lunch and poster session - Documentary film: The Champions
13:30 Latest news: Luminal ABC (Chairs: Bertha Aguilar Lopez, MX and Nagi S. El Saghir, LB)
Standards of care and optimal options (Joseph Gligorov, FR)
New targets, new drugs (Peter Schmid, UK)
Biology and resistance (Carsten Denkert, DE)
• Discussion
14:25 Specific sites of metastases (Chairs: Alexandru Eniu, RO and Sung-Bae Kim, KR)
• Update on systemic therapy of brain metastases (Nancy U. Lin, US)
• Leptomeningeal disease (Laura Biganzoli, IT)
• The role of new RT techniques for metastases treatment (Birgitte V. Offersen, DK)
• Discussion
15:35 Coffee break
16:00 Latest news: HER2+ ABC (Chairs: Ranjit Kaur, MY and Silvia Neciosup, PE)
• Standards of care and optimal options (Lisa A. Carey, US)
• New targets, new drugs (Javier Cortés, ES)
• Biology and resistance (Frédérique Penault-Llorca, FR)
• Discussion
17:00 Improving monitoring of efficacy and toxicity (Chairs: Olivia Pagani, CH and Shawna Rich-Ginsberg, CA)
• Implementing PROMs in clinical research and clinical practice (Lesley Fallowfield, UK)
• Optimal imaging techniques for bone only disease Frédéric (E. Lecouvet, BE)
• The role of liquid biopsies (Paul Mainwaring, AU)
• Discussion
18:00 Patient advocacy session: Improving your communication skills: the floor is yours
(Chairs: Shirley A. Mertz, US and Kirsten Pilatti, AU)
• Doctors need to believe in miracles too: ensuring you understand therapeutic aims of treatment
   recommendations (Lesley Fallowfield, UK)
• Building communication skills in health professionals – the role that advocates can play (Fran Boyle, AU)
• The power of storytelling in advocating for change - 3 case studies (Runcie C.W. Chidebe, NG - Shirley A.
   Mertz, US and Kirsten Pilatti, AU)
• Q&A session
18:00 Sponsored satellite symposium 5 (details are available HERE)


8:30 Consensus session (part I) (ABC5 chairs, Scientific Committee Members and Panellists)
10:30 Coffee break
11:00 Report from ABC Patient Advocacy Committee (Shirley A. Mertz, US)
11:15 Consensus session (part II) (ABC5 chairs, Scientific Committee Members and Panellists)
12:45 Close



ABC Global Alliance

ABC5 will be followed by the ABC Global Alliance meeting:
Part 1: Saturday, 16 November 2019, from 14:30 to 17:00, and
Part 2 : Sunday, 17 November 2019, from 8:30 to 13:00



Meeting room 3A/3B
14:30 Welcome, meeting overview and introduction (Fatima Cardoso, PT)
14:45 The ABC Global Alliance: overview of the initiatives implemented (Fatima Cardoso, PT)
15:10 Discussion and suggestions for 2020 (Moderators: Ranjit Kaur, MY and Kirsten Pilatti, AU)
15:45 Introduction to the Sunday workshops (Fatima Cardoso, PT and Lesley Fallowfield, UK)
16:00 Coffee break
16:30 Executive Committee 2019-2021 Election (Fatima Cardoso, PT - Renate Haidinger, DE and Shirley A. Mertz, US)


Meeting room 3A/3B
 8:30 Welcome and introduction (Fatima Cardoso, PT and Lesley Fallowfield, UK)
 8:40 Workshop (4 groups) (Moderators: Fran Boyle, AU - Lesley Fallowfield, UK - Belinda Kiely, AU and Luzia Travado, PT)
10:30 Coffee break
12:15 Report back from Groups
13:00 Meeting close (Fatima Cardoso, PT)


The Sunday workshops will be dedicated to discuss important communication issues related to ABC.
Four main questions will be asked to all participants:

1. What I wish I’d known about ABC/MBC before my diagnosis
2. Things I still don’t understand about ABC and treatment options
3. Things my Health Care Professionals did that a) helped b) didn’t help
4. Things friends and family could do to help when you have ABC

In order to allow participant to express their opinions, the audience will be divided in smaller groups and each group will discuss the same questions.
Answers will be collected, discussed, taking into account geographical and cultural differences, and conclusions and future actions will be agreed upon.

For further information about the ABC Global Alliance, please contact
Roberta Ventura, abcglobalalliance@eso.net, ph +41 91 820 0957

Poster session

BP: Best poster presentation; PO: Poster presentation

PO33     An innovative use of holistic needs assessments in secondary breast cancer. Catherine Bailey Catherine, UK
PO34     Recognising the need for specialist metastatic breast care nurses within Australia; Planning for ongoing education and placement of metastatic breast care nurses. Kerry Patford, AU
PO35     Nurses and patients interactive module for better treatment outcome. Chaturvedi Manju, IN
BP37     Benefit assessment of new metastatic breast cancer (MBC) treatments – a multi-stakeholder approach. Jenn Gordon, CA
BP38     How a web-based financial resources navigation tool can help patients manage the financial toxicity of breast cancer. Jenn Gordon, CA
BP39     Trastuzumab in metastatic breast cancer: how to make big things out of small pieces? Turki Mejri, TN
PO40     Designing a peer navigation program for patients with advanced Breast Cancer. Runcie Chidebe, NG
PO41     Diversional therapy for patients with advanced stage breast cancer. Ebele Nwankwo, NG
PO42     Return to work and financial toxicity of breast cancer patients in Japan. Naomi Sakurai, JP
PO43     ‘Metastatic breast cancer: the voice of patients and their families’. Milena Bourroul, BR
PO44     Patients’ preferences for breast cancer treatments: Subgroup analysis results from discrete choice experiment (DCE) survey in 4 European countries. Thomais Konstantopoulou, IT
PO45     Cancer support group: An advocacy and peer navigation tool for metastatic breast cancer patients. Mary-Gloria Anulika Orji, NG
PO46     Communication approach for better palliative care in rural India - BGO based approach. Nabanita Mandal, IN
PO48     Talking openly about metastatic breast cancer in Greece: the importance of different communication channels. Christiana Mitsi, GR
PO49     Recommendations to improve the lived experience of breast cancer patients in Canada. Cathy Ammendolea, CA
PO50     Quality & long life of advanced breast cancer patients. Chandra Rekha Gulabani, IN
PO51     “ABC Patients - oncologists communication” is a journey, not a destination. Rania Azmi, KW
PO52     Chemotherapy challenges in advanced breast cancers: An indian model of patient advocacy. Laleh Busheri, IN
PO53     Breast cancer education advocacy efforts. Pramod Pal, IN
PO54     Nutrient intake qualitatively & quantitatively of breast cancer patients undergoing chemotherapy at Dr Sardjito Hospital in Jogjakarta, Indonesia. Martalena Purba, ID
PO55     Comparative analysis of natural killer cell activity between advanced breast cancer and early breast cancer. Jae Il Kim, KR
PO56     The role of the allelic polymorphism of the CCR5 gene in locally advanced breast cancer of various molecular subtypes and its effect on the effectiveness of neoadjuvant chemotherapy. Nataliia Verovkina, UK
PO57     Liquid and tissue biopsy of female dogs with breast cancer: Identification of mutations in mTOR. Debora Zuccari, BR
PO58     Clinical impact of breast cancer stem cells in metastatic breast cancer patients. Mohamed Elbaiomy, EG
PO59     Early and advanced tumors can use two different strategies based on initial and profound abnormalities in microRNA pattern to acquire doxorubicin resistance. Volodymyr Halytskiy, UK
PO60     Assessment of the clinical features of inflammatory breast cancer patients in Puerto Rico reveals distinct receptor status. Michelle Martinez-Montemayor, PR
PO61     A new era in breast cancer therapy: Tumor targeting by conditioned medium from human amniotic membrane. Jafari Ameneh, IR
PO62     The effect of characterization self nanoemulsifying drug delivery system from the combination of gynura procumbens (Lour) merr and Pandanus conoideus lam. Extract on proliferative and apoptotic activity of breast cancer cell Line MCF-7. Mochamad Afifudin, ID
BP66     Sexuality assessment in women with advanced breast cancer. Marcelle Domingues M L, BR
PO67     Ribociclib (RIB) + letrozole (LET) in patients with hormone receptor-positive (HR+), human epidermal receptor-2–negative (HER2–) advanced breast cancer (ABC) by dose intensity: preliminary subgroup results from the phase 3b CompLEEment-1 trial. Fadi Farhat, LB
PO68     Ribociclib (RIB) + letrozole (LET) in older patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2– negative (HER2–) advanced breast cancer (ABC): subgroup results from the phase 3b CompLEEment-1 trial. Michelino De Laurentiis, IT
PO70     The metastatic receptor status impact on first-line treatment plans and clinical outcomes for recurrent metastatic breast cancer. Allen Pannell, US
PO71      A plain-language summary of the SOLAR-1 trial: studying alpelisib with fulvestrant in patients with HR+, HER2– advanced breast cancer who had previously received an aromatase inhibitor. Dawn Aubel, US
PO73     Real-world outcomes of patients with advanced breast cancer treated with palbociclib: a multicenter retrospective cohort study in Japan. Nina Odan, JP
PO74     A plain-language summary of the compLEEment-1 Study: Ribociclib and letrozole as first line therapy in a study of 3,246 people with advanced breast cancer. Ellen Warner, CA
PO75     Efficacy and tolerability of low dose metronomic chemotherapy (LDMC) in patients with metastatic breast cancer (MBC): a single center experience in West Sweden. Karolina Larsson, SE
PO76     The incidence of QT interval prolongation in patients with hormone receptor-positive, HER2-negative metastatic breast cancer treated with ribociclib combined with endocrine therapy in a real-world setting. Christian Martin Kurbacher, DE
PO77     New insights into how first recurrence at multiple metastatic sites influences survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 recurrent metastatic patients. Jun Yamamura, JP
PO78     Palbociclib in combination with endocrine therapy in patients with metastatic breast cancer: severe early hematological toxicity predictive factors. Léa Vazquez, FR
PO79     18-NaF PET-CT and metastatic breast cancer in an irish centre. Hazel O’Sullivan, IR
PO80     HER2-positive stage IV male breast cancer: prevalence and survival data from the United States. Ahmed Sohaib, EG
PO81     Men with breast cancer – survival and prognostic factors in the metastatic setting in Bulgaria. Assia Konsoulova, BG
PO82     Molecular profile of cases with Stage IV Breast Cancer in the United States (2010-2015), Mohamed Gouda, EG
PO83     Real-world survival data of palbociclib in advanced and metastatic breast cancer: a multicenter experience in Lebanon. Ahmad Ghoche, LB
PO84     The importance of HER2-ECD expression check for selection of anti-HER2 regimen for better outcome of HER2+ advanced and recurrent breast cancer. Noriko Miwa, JP
PO85     CDK inhibitors plus letrozole in first-line treatment HR-positive/HER2-negative advanced breast cancer (ABC) women with visceral disease: time to turn page? Elisa Gallerani, IT
PO86     Eribulin use and palliative care referral rates in metastatic breast cancer: Kent Oncology Centre experience. Claire Ryan, UK
PO87     Men with breast cancer – role of endocrine treatment for disease progression. Assia Konsoulova, BG
PO88     Real world data of cyclin-dependent kinase 4/6 inhibitors in a European and Latin-american Luminal advanced breast cancer population. Analysis of two centers. Juan Carlos Samamé Pérez-Vargas, PE
PO89     Treatment of premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer with an CDK4/6 inhibitor combined with endocrine agents: a real-world experience. Christian Martin Kurbacher, DE
PO90     Efficacy of eribulin in elderly patients (pts) with metastatic breast cancer (MBC) in real clinical practice in Russian Federation, Lubov Vladimirova, RU
PO91     Impact of Imaging Surveillance of Patients with Breast Cancer after Primary Treatment. Isabel Pereira, PT
PO92     Impact of real-world and clinical trial patients’ characteristics on the effectiveness and tolerability of iCDK in the treatment of advanced breast cancer. Inês Leão, PT
PO93     Advanced invasive lobular carcinoma, real world experiences in single institution. Junichiro Watanabe, JP
PO94     Impact of adding a platinum agent (Carboplatin) to Paclitaxel vs. Paclitaxel alone in MBC. A Romanian centre experience. Silvia Brotea-Mosoiu, RO
PO95     Treating bones in metastatic breast cancer. Elsa Campôa, PT
PO96     Preliminary analysis of treatment delay with Palbociclib on progression free survival (PFS). David da Silva Dias, PT
PO97     Women with metastatic breast cancer and bone marrow infiltration. Anna Andreadou, GR
PO98     Does local treatment affect outcome in patients with metastatic breast cancer? Singh Yadav Budhi, IN
 PO99     Hypofractionated radiotherapy for inflammatory breast cancer. Mohamed Ait Erraisse, MA
PO101     Concomitant chemoradiotherapy for unresectable non-metastatic inflammatoryand locally advanced breast cancer. Mohamed Ait Erraisse, MA
PO102     Hypofractionated radiation therapy: Could be considered as an option for the treatment of locally advanced breast cancer? Ghaiet el Fida Noubbigh, TU
PO104     Residual locally advance breast cancer after neoadjuvant systemic treatment: is surgery justifiable? Afsheen Javaid Khokher, PK
PO105     Men with breast cancer - surgical management in advanced and metastatic setting. Mariela Vasileva-Slaveva, BG
PO106     Electrochemotherapy for Cutaneous Metastasis of Breast Cancer. Update. Joana Bartolo, PT
PO107     Efficacy of surgical treatment of advanced breast cancer. Urgency of the problem. Michail J. Myasnyankin, RU
PO109     Self-management skills as predictors of positive affect and social well-being in metastatic breast cancer patients. Luzia Travado, PT
PO110     Emotional distress and brain functioning metabolism in metastatic breast cancer patients: a neuro-imaging study with 18F-FDG PET/CT, Joaquim C . Reis, PT
PO111     Evaluation of depression and anxiety in young women with metastatic breast cancer. Tahir Mehmood, PK
PO112     Quality of life and psychosocial needs of metastatic breast cancer patients, Tahir Mehmood, PK
PO113     Does being unmarried affect the time presentation and treatment compliance of patients with advanced breast cancer? Serene Tang Ee Ling, SG
PO114     Role of supportive care in improving quality of life and reducing unschedule hospital care. Lea Vazquez, FR
PO115     Validation of the CALM model, a brief psychotherapeutic intervention, for ABC patients in the Portuguese context: a SPARC MBC Challenge project. Luzia Travado, PT
PO117     Bone marrow breast carcinosis: Pathological, clinical parameters and outcome. A single institution’s experience. Nektarios Alevizopoulos, GR
PO118     Introducing a Mobile App for cancer care in Nigeria: Integrating the needs of advanced breast cancer patients. Runcie C.W. Chidebe, NG
PO119     “Factors influencing late presentation for health care among women with breast cancer attending Hospice Africa Uganda (HAU)". Nehemiya Igulu Bandese, UG
PO120     The SPARC metastatic breast cancer challenge: Our experience in Cameroon. Blaise Nkegoum, CM
 PO121     The reality of holistic treatment for advanced breast cancer patients in Ghana. Abena Addai, GH
PO122     A retrospective review of prognosis after completion of metastatic breast cancer specific treatments and hospital admissions in Somerset: Experience from a single centre. Saiqa Spensley, UK
 PO123     Hope for people living with metastatic breast cancer. Aditya Manna, IN
PO124     What needs to be done? Life quality assessment in advanced breast cancer patients. Chaturvedi Manju, IN
 PO125     Public health policy paper on counseling/rehabilitation needs for ABC in Asia. Pramod Pal, IN
BP126      “i’m still here”: insights into living – and dying – with advanced breast cancer in new Zealand. Adele Gautier, NZ
PO127     Feasibility and potential health benefits of an individualized physical activity intervention in women with metastatic breast cancer: Results of the ABLE single-arm trial study. Lidia Delrieu, FR
PO128     Epidemiological patterns of breast cancer. Nanuli Ninashvili, GE
PO129     Negative impact of disease progression on quality of life of patients with advanced breast cancer – Data from the TMK/MaLife-project. Norbert Marschner, DE
 PO130     Patient-reported outcomes (PRO) in patients (pts) with HER2- advanced breast cancer (ABC) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT): A focus on EMBRACA germline BRCA1 and BRCA2 mutation (gBRCA1/2m) subgroups. Anthony Gonçalves, FR
PO133     Health-related quality of life in 2nd-line endocrine therapy for patients with acquired endocrine-resistant postmenopausal ER-positive, HER2-negative metastatic breast cancer: the HORSE-BC study. Yuichiro Kikawa, JP
PO134     A five-year study of epidemiological trends and survival of advanced breast cancer in a Haitian cancer program. Joseph Jr Bernard, HT
PO135     Choice of therapy: clinicopathological factors and patient factors in elderly (80 years<) advanced breast cancer patients. Noriyoshi Fujisawa, JP
PO136     Radiofrequency ablation for liver metastases in the treatment of advanced breast cancer. Emanuela Ferraro, IT
PO137     Status of advanced breast cancer chemotherapy in resource poor nations. Pramod Pal, IN
PO138     Patterns of treatment failure and outcome in patients with triple negative breast cancer: Experience in a cancer center from North-East India. Sarathi Roy Partha, IN
PO139     Metastatic triple negative breast cancer to right colon; an unusual first presentation: A case report and literature Review. Nektarios Alevizopoulos, GR
PO140     Leptomeningeal carcinomatosis in patients with breast cancer: pathological, clinical parameters and outcome. A single institution’s experience. Nektarios Alevizopoulos, GR
PO141     A case report of breast cancer incidentally found during hematoma treatment. Eun Hwa Park, KR